BI Asset Management Fondsmaeglerselskab A S raised its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 662.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,290 shares of the medical research company's stock after purchasing an additional 17,630 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Exact Sciences were worth $1,140,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Asset Planning Inc acquired a new position in Exact Sciences in the fourth quarter worth approximately $40,000. Modus Advisors LLC acquired a new position in shares of Exact Sciences during the 4th quarter worth $43,000. AlphaQuest LLC raised its holdings in shares of Exact Sciences by 22,825.0% during the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock valued at $52,000 after purchasing an additional 913 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Exact Sciences in the 4th quarter valued at $66,000. Finally, Kieckhefer Group LLC acquired a new stake in shares of Exact Sciences in the 4th quarter valued at $188,000. 88.82% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research firms have weighed in on EXAS. Royal Bank of Canada initiated coverage on Exact Sciences in a report on Thursday, March 13th. They set a "sector perform" rating and a $52.00 target price on the stock. Mizuho began coverage on Exact Sciences in a report on Thursday, April 10th. They issued an "outperform" rating and a $60.00 target price for the company. Guggenheim reiterated a "buy" rating and set a $60.00 price target on shares of Exact Sciences in a report on Friday, April 11th. Scotiabank boosted their price objective on shares of Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 24th. Finally, Benchmark reiterated a "buy" rating and issued a $65.00 target price on shares of Exact Sciences in a report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $69.25.
View Our Latest Report on EXAS
Exact Sciences Stock Up 2.4 %
Shares of NASDAQ:EXAS opened at $44.15 on Wednesday. The company has a market capitalization of $8.20 billion, a PE ratio of -7.93 and a beta of 1.14. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. The company's fifty day moving average is $45.60 and its 200-day moving average is $54.62. Exact Sciences Co. has a 52 week low of $39.97 and a 52 week high of $72.83.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.23. The company had revenue of $713.42 million during the quarter, compared to analysts' expectations of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. Equities research analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.
Exact Sciences Profile
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
